After 15 years of training, excited to be starting as a Genitourinary Oncologist and Instructor @MSKCancerCenter! Very thankful to my wife & daughter who have put up with me during my training, the fellowship program, and all my incredible mentors along the way! @MSK_DeptOfMed

Results of the T-DXd/durva arm of #BEGONIA for 1L mTNBC are now out in @NatureCancer. High efficacy, with ORR 62% and mPFS 12.6 months. Strikingly, deep responses observed even in HER2-0 (null) dz, reminding that IHC is a poorly predictive ADC biomarker. nature.com/articles/s43018-0…

Lipid droplet is key in early antiviral defence!! Integrative proteomics and lipidomics reveals dual roles for lipid droplets in the host cell antiviral response. @nature nature.com/articles/s41467-0…

Online Now: Clonal lineage tracing of innate immune cells in human cancer dlvr.it/TStGjW

⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer. In a phase 3 study led by @EileenMOReilly and colleagues, patients receiving #daraxonrasib lived a median of 13.2 months compared with 6.7 months for those treated with chemotherapy. "To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease." Learn more: bit.ly/435pwKo

Live from @BuddyGuys in Chicago! #TheCheckPoints are bringing the energy tonight during #ASCO26. @sitcancer @FerranPrat5 @RPachynski @BReinfeld @jasonlukemd @wolchokj #ASCO26

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

Today at #ASCO26: MSK’s @jsmithymd shared his rapid oral abstract “A phase 2 trial of IO102-IO103 and nivolumab-relatimab in previously untreated, unresectable #melanoma.”

#TheCheckpoints are ready to get the party started @ASCO’s annual meeting! We had a great practice last night. 🎶🎸 Join us tomorrow night, Sunday, May 31, at 8 p.m. at Buddy Guy’s Legends in Chicago. @sitcancer @FerranPrat5 @RPachynski @BReinfeld @jasonlukemd @wolchokj #ASCO26

Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri #ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.

1/5 Cell identity is written in the proteome, not in the DNA, and not always in the RNA. Out on bioRxiv today: The first cell type-resolved, MS-based proteomic atlas of the human body. biorxiv.org/content/10.64898…

MSK physicians and scientists will join colleagues from around the world at the @ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago. MSK experts will present new research and clinical insights across gastrointestinal cancers, lung cancer, sarcomas, head and neck cancer, precision oncology, targeted therapies, radiation oncology, and more. Follow along as we share highlights from #ASCO26 and the latest advances in cancer research and care: bit.ly/4a9r1e8

PICI has named Rebecca Sager, urologic oncology fellow at @MSKCancerCenter, the inaugural recipient of the Conquer Cancer - Parker Institute for Cancer Immunotherapy Endowed Young Investigator Award. Dr. Sager is being recognized for her important research exploring tumor immunology and how treatments shape the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC). Her work represents the kind of innovative science that continues to advance the future of cancer immunotherapy and improve outcomes. Congratulations to Dr. Sager on this well-deserved recognition! parkerici.org/the-latest/dr-…

The "forbidden clones" that develop from somatic mutations and autoimmune diseases, theorized in 1959 but requiring state-of-the art sequencing to prove nature.com/articles/d41586-0…

Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis nature.com/articles/s41392-0…

No child deaths have been definitively linked to Covid vaccines, according to a report from the FDA that was quietly made public. nbcnews.com/health/health-ne…

This is insane lol

.@CharlesRudin named cancer center director at @MSKCancerCenter cancerletter.com/in-brief/20…

Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss. gift link nytimes.com/2026/05/21/scien…

Timely analysis from the trial that led to the approval of the first tumor-agnostic HER2-directed therapy in patients with HER2 IHC 3 advanced solid tumors, including advanced urothelial carcinoma. Discordance between local & central HER2 IHC scoring highlights the need for a standardized scoring system not only to identify patients eligible for Enhertu, but also those with HER2 IHC 1 /2 /3 expression who may be eligible for the growing number of HER2-directed clinical trials. aacrjournals.org/clincancerr… @OncoAlert @jamecancerdoc @koshkin85 @OncBrothers @DrKarineTawagi @CanDAydogdu @LauraBukavinaMD @emanuele_crupi @DanieleRaggi83 @niklas_kluemper @PTarantinoMD @Uromigos